Dataset Information

Method Comparison using DBS samples

ABSTRACT:

Metabolomics serves as a critical pillar in clinical research, yet the lack of standardized protocols often limits the comparability of data across different platforms and institutions. The HUMAN (Harmonizing and Unifying Blood Metabolomics Network) has as one of its goals to to advance the field of metabolomics by performing cross-laboratory comparisons, integration and co-evaluation of data analysis tools. The present Ring Trial was established as a multi-center collaborative effort to address these inconsistencies by systematically evaluating the impact of varying analytical setups on metabolite detection and identification. While the broader initiative encompasses multiple phases of standardization, the present work focuses specifically on the Phase 2 of the ring trial, which evaluates the analytical robustness of Dried Blood Spot (DBS) analysis.

In this phase, whole blood samples from 10 healthy individuals were used to create a controlled 'artificial metabolic disruption' model. Samples were divided into two cohorts: one unspiked and one spiked with a blinded mixture of 12 endogenous metabolites and 8 exogenous compounds at varying concentrations. These samples were spotted onto Whatman cards to simulate real-world clinical specimens. Participating laboratories analyzed the blinded samples using both a common harmonized LC-MS method and their own lab-specific protocols to assess the recovery and accurate annotation of these 'artificial biomarkers.' By comparing results across diverse mass spectrometry platforms, this study quantifies the efficiency of different workflows in identifying unknown compounds in complex matrices. The current report is dedicated exclusively to the methodology and outcomes of this second phase analyzed at the BIOMIC laboratory at Aristotle University of Thessaloniki.

INSTRUMENT(S): Liquid Chromatography MS - negative - reverse-phase, Liquid Chromatography MS - positive - reverse-phase

PROVIDER: MTBLS14519 | MetaboLights | 2026-05-19

REPOSITORIES: MetaboLights

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	a_MTBLS14519_LC-MS_negative_reverse-phase-3.txt	Txt
	a_MTBLS14519_LC-MS_negative_reverse-phase.txt	Txt
	a_MTBLS14519_LC-MS_positive_reverse-phase-2.txt	Txt
	a_MTBLS14519_LC-MS_positive_reverse-phase-3.txt	Txt
	i_Investigation.txt	Txt

Items per page:

1 - 5 of 10

Similar Datasets

Project description:Abstract: Hematopoietic stem cells (HSCs) are used in transplantation therapy to reconstitute the hematopoietic system. Human cord blood (hCB) transplantation has emerged as an attractive alternative treatment option when traditional HSC sources are unavailable, however, the absolute number of hCB HSCs transplanted is significantly lower than bone marrow or mobilized peripheral blood stem cells (MPBSCs). We previously demonstrated that dimethyl-prostaglandin E2 (dmPGE2) increased HSCs in vertebrate models. Here, we describe preclinical analyses of the therapeutic potential of dmPGE2-treatment using human and non-human primate HSCs. dmPGE2 significantly increased total human hematopoietic colony formation in vitro and enhanced engraftment of unfractionated and CD34+ hCB following xenotransplantation. In non-human primate autologous transplantation, dmPGE2-treated CD34+ MPBSCs showed stable multilineage engraftment over one year post-infusion. Together, our analyses indicated that dmPGE2 mediates conserved responses in HSCs from human and non-human primates, and provided sufficient preclinical information to support proceeding to an FDA-approved phase 1 clinical trial. In order to identify the potential mechanism of action of dmPGE2 on gene expression and HSC function, and to possibly explain the muted response of rhesus CD34+ MPBSCs to dmPGE2 exposure, microarray gene expression analysis was conducted. Human and rhesus CD34+ MPBSCs were exposed to DMSO control or dmPGE2 at a dose of either 10 and 50 uM as described above, and processed for microarray analysis at 0, 2, 6, 12 and 24 hours post treatment. Four human donors contributed 8 to 10 samples each at varying time points and dosage for a total of 37 samples (2 samples were technical repeats). Six rhesus macaques contributed 3 to 9 samples each at varying time points and dosage for a total of 28 samples (4 samples were technical repeats). Pooled PBMC's from 6 donors aphereses were used as a reference sample.

Dataset Information

Method Comparison using DBS samples

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets